Peptron
Financials
Valuation Metrics
Peptron's Market Cap is ₩4.1T. At end of 2025 it was ₩5.9T. Ranked #115 of 2,436 in KR market (top 5%), #11 of 1,649 on KOSDAQ (top 0.7%), #10 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 4.05T KRW | KR#115/2,436 Sec#10/234 |
| Revenue | 5.98B KRW | KR#2,333/2,436 Sec#190/234 |
| Net Income | -16.62B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 174.46B KRW | KR#1,371/2,436 Sec#104/234 |
| Net Assets | 135.97B KRW | KR#1,172/2,436 Sec#89/234 |
| Employees | 112 | KR#1,546/2,436 Sec#120/234 |
| Value | ||
| P/B | 29.80x | KR#2,397/2,436 Sec#225/234 |
| P/S | 677.55x | KR#2,407/2,436 Sec#223/234 |
| FCF Yield | -0.57% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -12.22% | KR#1,943/2,436 Sec#150/234 |
| ROA | -9.52% | KR#2,062/2,436 Sec#157/234 |
| Op. Margin | -379.24% | KR#2,362/2,436 Sec#199/234 |
| Revenue Growth | 21.38% | KR#616/2,436 Sec#58/234 |
| Financial Health | ||
| Debt Ratio | 128.30% | KR#816/2,436 Sec#96/234 |
| Total Debt | 29.68B KRW | KR#1,195/2,436 Sec#95/234 |
| FCF | -23.08B KRW | KR#1,936/2,436 Sec#186/234 |
| Cash | 10.59B KRW | KR#1,643/2,436 Sec#128/234 |
| Current Ratio | 12.19x | KR#71/2,436 Sec#20/234 |
| Performance | ||
| 1Y Return | -40.88% | KR#1,857/2,436 Sec#164/234 |
| 1M Return | -3.82% | KR#1,286/2,436 Sec#130/234 |
| From 52W High | -55.72% | KR#1,487/2,436 Sec#126/234 |
| 1Y MDD | -73.16% | KR#2,071/2,436 Sec#184/234 |
| Trading | ||
| Volume | 504,840 shares | KR#271/2,436 Sec#28/234 |
| Foreign Own. | 4.32% | KR#858/2,436 Sec#81/234 |
| Per Share | ||
| EPS | -713 KRW | KR—/2,436 Sec—/234 |
| BPS | 5,850 KRW | KR#1,321/2,436 Sec#96/234 |
Company Info
Peptron, established in 1997 for biotechnology advanced material manufacturing and pharmaceutical R&D, was listed on KOSDAQ in 2015. The company develops pharmaceuticals based on peptide engineering and drug efficacy sustaining original technology, securing clinical trial and commercialization capabilities through GMP mass production facilities. With its SmartDepot technology, Peptron can develop various pharmaceuticals, accelerate its contract drug development and manufacturing business, and conduct research on metabolic disease treatments and anticancer drugs. The company is headquartered in Yuseong-gu, Daejeon.